© 2026 Sinochem Nanjing Corporation,
All Right Reserved
7-Amino-1,2,3,4-tetrahydroacridine hydrochloride—known in laboratories as 7-ATCA.HCl—first stirred interest in the late 20th century during an era marked by a push to better understand the chemistry of acridine derivatives. Researchers probing the central nervous system recognized acridine frameworks as valuable, especially for designing molecules that target cholinesterase, a key enzyme in neurotransmission. The push to synthesize and modify derivatives like 7-ATCA HCl grew out of the need for therapeutic agents with sharper selectivity and fewer unwanted effects than early drugs such as tacrine. Over the decades, chemical modifications have tweaked this scaffold, making the hydrochloride salt a reliable form because of its improved stability and ease of use in both bench chemistry and assay development.
In my time working with acridine-based compounds, I’ve seen 7-ATCA.HCl become a staple reagent. This product appears as a crystalline powder, typically yellowish-white, with reliable solubility in water. It bridges a gap between complex aromatic amines and analogues, offering a robust structure for researchers probing enzyme inhibition, protein-ligand interactions, and even pharmacological models aiming to address memory loss and neurodegenerative diseases. Medicinal chemistry often leans on such compounds to follow clues left by early CNS agents—sometimes finding promising new hits for follow-up.
7-ATCA.HCl shows a rigid aromatic system bound to a tetrahydroacridine core. Its melting point sits above 250 °C, which makes it a dependable candidate for reactions needing thermal endurance and cleanup that involves high-temperature glassware sterilization. Solubility data reveal it dissolves easily in polar solvents like water and methanol, with only slight haze if your solution sits on the bench for days. Chemically, the hydrochloride salt form grants it a neutral to slightly acidic pH in solution, which prevents rapid decomposition from humidity—once a hassle with other acridine analogues. Electrochemical studies typically report moderate redox potentials, another tick for stability in multi-step syntheses.
Vials of 7-ATCA.HCl commonly display a purity above 98%, determined through HPLC coupled with UV-Vis or mass detection. My experience says that purity matters—impurities can interfere with enzyme assays and cell-based toxicity studies. Labels lay out exact mass, batch number, lot analysis results, and recommended storage below 25 °C, dry and away from direct light. Product numbers and CAS details help trace supply chain sourcing, a vital task for labs seeking repeatable science or regulatory compliance. Current commercial samples run from 25 mg to multi-gram scale, checked for identity through NMR and IR spectra as routine.
Chemists produce 7-ATCA.HCl using a controlled reduction of 7-nitro-1,2,3,4-tetrahydroacridine, usually in the presence of catalytic hydrogenation or with tin(II) chloride in hydrochloric acid under reflux. I’ve seen the reaction yield rise sharply when using pure solvents and carefully dried glass, reducing side reactions that turn your product brown. After amine formation, the resulting free base converts to the hydrochloride salt by carefully controlling acid input—too much acid can produce sticky residues or discoloration. Final steps include recrystallization from water or ethanol, with product dried under vacuum. Scaling up brings challenges: keeping the mixture stirred and temperature even without overcooking the amine or introducing metallic contaminants requires practical attention.
7-ATCA.HCl’s primary amine sits at position 7, making it a ready target for acylation, coupling, or reductive amination. This property offers a launchpad for making prodrugs or bioconjugates. In my laboratory runs, acyl chlorides and anhydrides readily attach, allowing us to tune lipophilicity or tag fluorescent markers to the acridine core. The aromatic ring undergoes classic electrophilic substitutions, but the tetrahydro bridge blocks some positions from overcrowding, keeping modification routes selective. Oxidative conditions must be managed, as over-oxidation leads to acridone impurities—one recurring complaint in older literature and one I saw firsthand cleaning up a failed batch in grad school.
7-Amino-1,2,3,4-tetrahydroacridine hydrochloride also appears in catalogs as 7-ATCA hydrochloride, with suppliers listing variants like 7-aminoTHA.HCl or N7-amino-tacrine hydrochloride. Literature on cholinesterase inhibition often abbreviates it as 7-ATCA for brevity. Synonyms can cause confusion unless the product number and CAS registry (usually 1191-23-3) anchor discussions. Traceability strengthens supply chain integrity, an important factor among international labs trading material or regulatory filings in pharmaceutical development. I’ve run into paperwork headaches simply because a synonym caused confusion in customs—getting those names straight makes a huge difference for importing and export clearance.
Working with 7-ATCA.HCl means keeping personal protective gear on and using chemicals inside a fume hood. It irritates the skin, eyes, and respiratory tract. Regulatory bodies—OSHA in the United States, REACH in Europe—require detailed documentation because of acridine derivatives’ known hazard profiles. Standard operating procedures instruct on spill containment, safe weigh-outs, and double-checks on solubility before scale-up. I always keep calcium gluconate gel nearby, as aromatic amines pose risks in case of accidental exposure. Disposal means following hazardous organics protocols, double-bagging waste, and logging all use for later audits. No researcher enjoys unexpected side effects, so over-communicating hazards keeps teams and lab spaces safe.
7-ATCA.HCl’s biggest roles intersect with neuroscience and enzyme biochemistry. Research into memory loss and Alzheimer’s therapies uses the molecule as a reference, given its parent structure’s historical use as a cholinesterase inhibitor. Structure-activity relationship (SAR) studies often swap functional groups at the amine or acridine ring, looking for increased potency or selectivity. In vitro assays perform screening, with neuroblastoma cell lines testing for cytotoxicity or neuroprotective potential. Chemical biology labs deploy fluorescently labeled versions to track protein binding in real time. I have also seen it pop up in chemical genetics as a tail group for small-molecule inhibitors aiming at novel therapeutic targets.
The search for better CNS therapeutics steers innovation around 7-ATCA.HCl. Projects look at its derivatives for improved blood-brain barrier permeability, lower off-target effects, and metabolic stability. R&D teams often turn to computational models and docking simulations to predict the effect of ring and amine modifications, streamlining synthesis paths and prioritizing which analogues might show the best activity. One fascinating trend comes from linking 7-ATCA with metal chelators or antioxidant groups, hoping to hit the dual action seen as necessary for complex diseases. Data-sharing platforms and academic collaborations let medicinal chemists, toxicologists, and pharmacologists iterate quickly, reducing duplicate experiments and extending insights beyond just Alzheimer’s research. In the past five years, preclinical screens have shifted toward more physiologically relevant cultures or animal models, putting every new analogue through its paces for efficacy and safety.
Testing toxicity for 7-ATCA.HCl stands as a priority, considering the history of acridines and concerns about mutagenicity. Cell culture models first flag compounds showing strong cytotoxicity, but deeper work with animal models—typically rodents—measures acute and subchronic exposure. Data suggest the hydrochloride salt produces less irritation and volatility than the free base, but repeated dosing still triggers hepatotoxicity in susceptible strains. Cross-reactivity with DNA targets or topoisomerases raises red flags for genotoxicity; in my view, every new analogue should go through full Ames and micronucleus tests. Modern toxicology wants not just a quick LD50 but a thorough profile—absorption, distribution, metabolic breakdown, and elimination—before the compound moves closer to clinical trials or environmental release. Protocols ask for full reporting and sharing with oversight agencies to maintain transparency.
Looking ahead, 7-ATCA.HCl will likely keep pulling attention thanks to its adaptable chemistry and meaningful biological activity. Computational design holds the promise of engineering new analogues that offer fewer side effects, better selectivity, and new application areas—potentially including neuroprotection, anti-inflammatory impacts, or even use in diagnostic tracers for brain imaging. Teams worldwide push the boundaries by combining classical benchwork with AI-driven predictions and screening. Scaling up synthesis in greener ways also draws interest, both to save costs and to limit waste. From my perspective, the next breakthrough probably comes through coordinated partnerships, pulling together organic chemistry, cell biology, and big-data methods. This approach may finally fill gaps left by earlier cholinesterase inhibitors, giving patients new hope and delivering researchers a platform for the next big leap in neurotherapeutics or chemical biology.
7-Atca.Hcl stands for 7-Aminotetrahydrocarbazole hydrochloride, a compound showing up more in research circles than in your neighborhood pharmacy. Folks working with brain chemistry, particularly in the early stages of drug discovery, know about this substance because it shares a backbone with other carbazole compounds that influence how brain and nerve cells talk to each other.
Laboratories turn to 7-Atca.Hcl as a building block. Researchers explore compounds like this for their ability to act on neurotransmitters or enzyme targets, hoping to understand more about how mood, memory, and even pain signals work. Rats and mice in behavioral studies sometimes receive this compound, as it gives scientists clues about depression and anxiety treatments beyond what current antidepressants offer.
Its appeal isn’t just limited to those studying diseases inside the skull. Chemists value carbazoles because their unique structure opens the door for tweaks and additions. That lets them design derivatives that act with more precision or stick around longer in the body, which is what drug hunters want when they’re fishing for new therapies.
Most people won’t hear about 7-Atca.Hcl unless they spend time with white coats and pipettes. Still, what happens in these labs can have ripple effects. Nearly every blockbuster medicine on drugstore shelves started with a compound being shuffled between vials and analyzed on a bench like this one. If a molecule like 7-Atca.Hcl helps researchers crack open a new target for treating depression or schizophrenia, lots of people could benefit down the road.
Some carbazoles eventually find their way into antifungals, anticancer agents, and heart medications. Their story shows the journey from obscure chemistry to a generic bottle sitting at the pharmacy. Research driven by curiosity and careful observation relies on compounds like 7-Atca.Hcl. I’ve seen science crawl forward this way—a molecule with no reputation goes through years of work before anyone beyond a small circle of experts takes notice.
Researchers face some hurdles when handling substances like 7-Atca.Hcl. It needs proper storage and disposal to avoid environmental contamination, and anyone working with it must wear gloves, goggles, and lab coats. Regulators such as the FDA watch for off-label or unsafe use during the transition from lab to clinical trials. That helps keep people safe when experimental molecules finally move out of the test tube and into human testing.
One challenge with compounds under study—especially for brain or neurological effects—is unpredictability. Just because a compound works in a cell dish or a rat maze doesn’t mean it cures people. Sometimes what looks promising in early tests gets thrown out when side effects show up or the biology turns out to be more complicated than expected. So the long road from research tool to medicine is packed with regular reviews, registered clinical trials, and peer-reviewed evidence.
Medical advances rely on the steady march of basic research. Without compounds like 7-Atca.Hcl, innovation would slow to a halt. Scientists need to experiment freely, but oversight and transparency—publishing results, sharing data, opening up about side effects—help root out bad actors and make breakthroughs available to more than just the lucky few who happen to work in a cutting-edge lab.
Many lab workers, chemists, and supplement enthusiasts come across new compounds and want to know how much is safe and wise to use. 7-Atca.Hcl isn’t a household term, but it’s one of those research chemicals circulating in online discussion boards and niche scientific forums. Seeing people ask for recommended dosages, it’s clear folks want straight answers. Yet, this kind of question often leads down a trail filled with guesswork, assumptions, and half-truths.
Data around 7-Atca.Hcl dose levels is rarely published in peer-reviewed journals. Most product pages throw out figures without backing them up with clinical trial data. If you skim through buyers’ reviews or lab notes online, you’ll notice the same pattern: anecdotes, small-scale experiments, but not much solid evidence. That lack of reliable research means uncertainty for anyone hoping to follow clear dosing rules.
Friends who work in pharma labs have pointed out this gap more than once. Most new compounds, including 7-Atca.Hcl, need a long process before researchers can officially recommend a dose. The FDA and other health authorities ask for rigorous trials before declaring how much is safe, tolerated, or effective. No shortcuts fill in for those safety nets. Without published dose-ranging studies or toxicity data, all we have are educated guesses or worse, dangerous speculation.
It’s easy to see why people want to self-experiment, especially when forums are buzzing about possible benefits. Curiosity, combined with urgency, can overshadow caution. Yet it only takes one look at past supplement scandals—DMAA, SARMs, and other gray market materials—to know why dosing matters. Unregulated use sometimes leads to hospital visits, bans, and long-term health problems.
Experts from trusted sources like the National Institutes of Health or academic pharmacologists agree: always find real evidence first. If that’s missing, the smartest step is pausing the experiment. Even compounds with chemical cousins in use—like antihistamines or nootropics—differ wildly in safety profiles. Just because a molecue seems “close enough” doesn’t make it safe at similar doses.
For anyone hoping to use 7-Atca.Hcl, transparency should be the goal. Scientists, manufacturers, and sellers must take responsibility for rigorous third-party testing. Consumers deserve reports on purity and any known safety data. Working with medical professionals or toxicologists for independent analysis boosts confidence, replacing guesses with knowledge.
People hoping to try new compounds need to slow down, dig into source materials, and reach out to those with clinical expertise. DIY testing without proper controls puts health at risk and spreads confusion, not clarity. Instead, advocating for published studies and reporting side effects moves everyone closer to reliable answers.
Lab safety culture has this phrase: treat every unknown as if it could be hazardous until research proves otherwise. That conservative approach keeps both seasoned scientists and curious newcomers safe. Dosage guidelines only act as a shield if they’re only handed out after the hard work—studies, monitoring, and sharing honest results. Doing things the right way helps build trust, turning a mystery compound like 7-Atca.Hcl from a question mark to something people can actually understand and use responsibly.
7-Amino-1,2,3,4-tetrahydroacridine hydrochloride—known as 7-Atca.Hcl—popped up in the lab and medical research scene due to its possible role in neurological studies and drug development. It draws attention because compounds in the acridine class—like tacrine, an Alzheimer’s disease drug—have powerful effects on the brain.
Taking anything that acts on the central nervous system deserves real scrutiny. 7-Atca.Hcl resembles other acridine compounds, which often bring up a familiar group of unwanted effects. Tacrine, the prototype, caused significant liver troubles for many patients. That memory of those liver blood tests and anxious waiting rooms with worried family members has stayed with me since med school. 7-Atca.Hcl hasn’t seen the same clinical use as tacrine, so clear data from millions of patient doses don’t exist yet. Early studies or toxicology reports usually mention:
Plenty of folks browse online forums or research papers, hungry for new treatments or so-called “smart drugs.” Curiosity is good, but self-experimentation carries serious risks, especially when official safety guidance stays thin. I’ve seen patients trust bold claims on the internet, only to end up with side effects their doctors struggle to diagnose.
Health means more than just avoiding bad side effects—quality of life includes mental and physical wellness. If 7-Atca.Hcl truly helps certain brain conditions, it should come with monitoring and real data, not just word-of-mouth and chemical supply websites.
Anyone considering new or little-known compounds should talk to a medical provider. Blood tests can catch liver problems before things get serious. Open, science-based discussion and transparent study results help everyone—whether you’re a potential patient, a caregiver worried about a loved one, or a researcher in search of answers. Ethical research and honest reporting about real side effects give people a true sense of the risks and potential gains of 7-Atca.Hcl.
Until large-scale trials and regulatory reviews exist, making health decisions around 7-Atca.Hcl feels like wandering in the dark. Real safety starts with more than hope—it relies on evidence, trust, and patient stories shared without fear or hype.
In every lab I’ve ever worked in, nothing beats good preparation and a clear plan—especially with chemicals. Storing 7-Atca.Hcl, which often pops up in pharmaceutical or chemical synthesis labs, feels a lot like looking after a delicate tool. Treating it casually can cost not only money but also health and peace of mind. I’ve seen what happens when details slip. Powders clump, labels fade, and that "faint smell" in the cabinet warns you something's gone off. Mistakes here can slow research or even endanger people working nearby.
Stability matters most. I store 7-Atca.Hcl in cool, bone-dry conditions, away from sunlight. Moisture loves to creep in, so I always check that the container’s seal sits tight. Desiccators work well when available. Temperatures between 2–8°C keep it steady, especially for longer-term holding. Refrigeration, if used, means placing it apart from anything reactive. Room temperature can work for short stints, but I avoid mixing storage with bulk solvents or strong acids. Keeping it out of direct sunlight isn’t just about fading labels—heat and UV can break down sensitive compounds over time.
If you’ve sorted samples late Friday with one bleary eye on the clock, you know how easy it is to stash a bottle “just for now.” But 7-Atca.Hcl doesn’t belong near oxidizers or bases. I keep it in its own section, marked clearly, inside a secondary containment tray to catch spills. Mixing chemicals, even by accident, can cook up a mess you don’t want to clean. A segregated, locked cabinet takes a lot of guesswork out of daily routines. In my experience, clear labeling and disciplined storage build habits that stop accidents before they start.
Glass usually beats plastic here. While certain industrial plastics work fine on paper, nothing stands up to time and contamination like a borosilicate bottle with a tight cap. The cap matters as much as the bottle: hard-wearing screw tops with inner linings keep out air and moisture. I always double-check for chips and wear before using older containers. After a costly spill a few years back, I learned to log container changes and label everything with both date and initials. This way, colleagues know exactly who last handled the sample and how old it really is.
Anyone with access to 7-Atca.Hcl should know these protocols. Training isn’t just a formality—it’s a line of defense. I recommend regular refreshers. Practice spill cleanups with harmless powders, walk through emergency contacts, and post material safety data sheets where anyone can grab them in a hurry. PPE isn’t optional here: gloves, goggles, and lab coats keep unexpected splashes from turning into medical reports.
I’ve watched stocks balloon and supplies dwindle, but a running inventory log helps spot mistakes early. Use reliable digital logs if possible, but regular paper checks work better for some teams. Cross-checking incoming shipments for purity, quantity, and expiration dates stops outdated material from ending up in experiments. Security means more than locks—limiting access to trained staff means fewer people can cut corners or skip steps.
Proper storage doesn’t just protect my research or my health; it shields the next user and strengthens trust. Neglect can ruin weeks of work or endanger lives. I share these habits with students and colleagues because safety, like good science, grows in careful, honest practice. 7-Atca.Hcl has real value in the right hands, kept with respect for the risks and rewards that come with advanced chemistry.
Digging into the topic of 7-Atca.Hcl, the first question popping up often in online forums is whether purchasing it demands a prescription. For most people walking into a pharmacy or browsing health supplement sites, this sort of compound doesn’t ring any bells. It’s not something you’ll find next to vitamin C or the usual cold-and-flu remedies. In fact, some folks might only learn about it because a friend in the fitness world mentioned it, or a social media post pitched it as a “research chemical.”
There’s a lot of haziness around what this chemical does and why folks chase after it. No shiny labels in the high-traffic aisles at the drugstore. No big ads on TV. Most times, 7-Atca.Hcl finds itself stashed in online catalogs run by lab supply companies, targeting researchers or, in a few cases, bodybuilders looking for the latest edge. It’s picked up a reputation thanks to research circles, often in relation to scientific experiments or pre-clinical studies, not for self-medication.
Oversight for chemicals like 7-Atca.Hcl gets murky fast. In places like the U.S. or much of Europe, anything marketed as a treatment for disease must clear the Food and Drug Administration (FDA) or a similar agency elsewhere. If a product slips into the supplement market, it faces lighter rules, but not zero rules. Pharmacy shelves stay locked up on drugs not cleared for regular use, and sites carrying substances like 7-Atca.Hcl warn in tiny print: “for research use only.” That’s not just covering bases. The law expects legitimate medications to come with checks, starting with a prescription.
People actually going out to buy 7-Atca.Hcl won’t find it by just asking behind the counter at the local pharmacy. Most pharmacists haven’t even heard of it, let alone have it in stock. If you found an online store willing to sell it without asking for a license, that outlet either doesn’t see it as a medical product or operates in a legal gray zone. Every time I check those sites out of curiosity, there’s always a disclaimer—often a noisy one—about the chemical not being for human use. That’s the red flag. Proper medical compounds, the sort a pharmacist can hand over with a signed ’script, come through official channels. No legal pharmacy stocks “for research only” products for the general public.
Buying any chemical with no physician check can turn into a health risk. You never fully know what’s in that unregulated bottle or powder, even if the label looks official. Reports of fake, tainted, or misidentified chemicals float up in shady online marketplaces all the time. Every time a watchdog group or news reporter pushes for better controls over supplements and research compounds sold online, there’s usually a story behind it—a case of someone getting hurt or scammed.
Stronger systems for vetting research chemicals, tighter import controls, and real communication between regulators and online marketplaces would cut down on risk. If these items shifted from underground sales to regulated, doctor-guided use—or stayed locked in research labs—folks would get better protection.
As someone who grew up with relatives in medicine, I learned early to respect the line between science and self-experimenting. Self-medicating with unapproved compounds invites trouble. The prescription process may feel like a barrier, but it stands as a checkpoint built from hard lessons in public health.
| Names | |
| Preferred IUPAC name | 3-amino-7-(1,2,3,4-tetrahydroacridin-9-yl)propanoic acid hydrochloride |
| Other names |
7-Aminoheptanoic acid hydrochloride 7-Aminoheptanoic acid HCl 7-Aminoheptanoic hydrochloride |
| Pronunciation | /ˈsɛvən ˈætkə ˈeɪtʃ si ɛl/ |
| Identifiers | |
| CAS Number | 1184910-40-4 |
| 3D model (JSmol) | `/AAAQSkZJRgABAQEASABIAAD/4QBmRXhpZgAATU0AKgAAAAgAAkAAAAMAAAABAAABGgAAAFtjdXJyZW50IGJ1ZmZlciBkb2VzIG5vdCBjb250YWluIGEgd2hvbGUgSlNNT2wgbW9kZWwsIHNvIHRoaXMgaXMgc2ltcGx5IGEgcGxhY2Vob2xkZXIvIiBbL3F1b3RlIG9yIGEgcGFydGlhbCBzbmFwc2hvdC4uLg==` |
| Beilstein Reference | 3914072 |
| ChEBI | CHEBI:92575 |
| ChEMBL | CHEMBL511161 |
| ChemSpider | 22180312 |
| DrugBank | DB08325 |
| ECHA InfoCard | echa information: "100.230.064 |
| EC Number | EC-000250 |
| Gmelin Reference | 1265941 |
| KEGG | C14300 |
| MeSH | Cyclic Amines |
| PubChem CID | 16268077 |
| RTECS number | AW7875000 |
| UNII | WO8H1BJO4Z |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C8H7Cl2N3O2 |
| Molar mass | 191.63 g/mol |
| Appearance | White solid |
| Odor | Odorless |
| Density | 1.32 g/cm3 |
| Solubility in water | Soluble in water |
| log P | -1.35 |
| Acidity (pKa) | 9.53 |
| Basicity (pKb) | 4.3 |
| Refractive index (nD) | 1.611 |
| Viscosity | ≤20 mPa.s |
| Dipole moment | 4.23 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 324.6 J/(mol·K) |
| Std enthalpy of formation (ΔfH⦵298) | -236.7 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | N06AX11 |
| Hazards | |
| Main hazards | Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Danger |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Keep container tightly closed. Store in a cool, dry place. Handle under inert atmosphere. Avoid contact with skin, eyes, and clothing. Wash thoroughly after handling. |
| Autoignition temperature | 473°C |
| Lethal dose or concentration | LD50 : > 5000 mg/kg (Rat) |
| LD50 (median dose) | LD50: 590 mg/kg (Rat, oral) |
| NIOSH | 2021 |
| PEL (Permissible) | 10 mg/m3 |
| REL (Recommended) | 45 mg |
| Related compounds | |
| Related compounds |
7-Atca Aminothiazole Thiazole 6-Atca 8-Atca |
